Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum-Reference-Cited by-同舟云学术

Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum

Published:2022-11 Issue:11 Volume:24 Page:2029-2036
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European J of Heart Fail

Author:

Butler Javed¹²,Usman Muhammad Shariq¹,Anstrom Kevin J.³,Blaustein Robert O.⁴,Bonaca Marc P.⁵,Ezekowitz Justin A.⁶,Freitas Cecilia⁷,Lam Carolyn S.P.⁸,Lewis Eldrin F.⁹,Lindenfeld JoAnn¹⁰,McMullan Ciaran J.⁴,Mentz Robert J.³,O'Connor Christopher³¹¹,Rosano Giuseppe M.C.¹²,Saldarriaga Clara Inés¹³,Senni Michele¹⁴,Udelson James¹⁵,Voors Adriaan A.¹⁶,Zannad Faiez¹⁷

Affiliation:

1. Department of Medicine University of Mississippi Medical Center Jackson MS USA

2. Baylor Scott and White Research Institute Dallas TX USA

3. Duke University Medical Center and Duke Clinical Research Institute Durham NC USA

4. Cardiovascular Diseases, Merck & Co., Inc. Kenilworth NJ USA

5. Division of Cardiology, Department of Medicine University of Colorado School of Medicine Aurora CO USA

6. Division of Cardiology, Mazankowski Alberta Heart Institute University of Alberta Edmonton Alberta Canada

7. Pharmaceuticals Research & Development, Bayer AG Wuppertal Germany

8. National Heart Centre Singapore and Duke National University of Singapore Singapore Singapore

9. Department of Cardiovascular Medicine Stanford University Stanford CA USA

10. Vanderbilt Heart and Vascular Institute Vanderbilt University Medical Center Nashville TN USA

11. Inova Heart and Vascular Institute Falls Church VA USA

12. Department of Medical Sciences IRCCS San Raffaele Pisana Rome Italy

13. Cardiology Department Universidad de Antioquia Medellín Colombia

14. Cardiologia 1, ASST Papa Giovanni XXIII Bergamo Italy

15. Division of Cardiology and the CardioVascular Center Tufts Medical Center Boston MA USA

16. Department of Cardiology University of Groningen, University Medical Centre Groningen Groningen Netherlands

17. Université de Lorraine, Inserm INI‐CRCT, CHRU Nancy France

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2720

Reference32 articles.

1. Risk Profiles in Heart Failure

2. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction

3. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure

4. Contextualizing Risk Among Patients With Heart Failure

5. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vericiguat attenuates doxorubicin-induced cardiotoxicity through the PRKG1/PINK1/STING axis;Translational Research;2024-11

2. New Therapeutics for Heart Failure Worsening: Focus on Vericiguat;Journal of Clinical Medicine;2024-07-19

3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial;Frontiers in Pharmacology;2024-06-12

4. 2024 update in heart failure;ESC Heart Failure;2024-05-28

5. Improving therapeutic outcomes in heart failure with reduced nonvalvular ejection fraction: A clinical study of heart failure education intervention;Clinical Cardiology;2024-04-29